NextCure (NXTC) Price & Analysis

Compare

318 Followers

NXTC Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.69 - $19.20

Previous CloseN/A

Volume33.57K

Average Volume (3M)218.54K

Market Cap

$13.22M

Enterprise Value-$16.89M

Total Cash (Recent Filing)$35.31M

Total Debt (Recent Filing)$4.67M

Price to Earnings (P/E)―

Beta0.96

Next Earnings

Oct 30, 2025

EPS Estimate

-3.98

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-11.29

Shares Outstanding2,676,110

10 Day Avg. Volume12,739

30 Day Avg. Volume218,541

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-1.28

Enterprise Value/Revenue-5.15

Enterprise Value/Gross Profit48.83

Enterprise Value/Ebitda0.27

Forecast

1Y Price Target

$17.50

Price Target Upside260.82% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe Phase 1 dose-escalation trial for LNCB74 in breast, ovarian, and endometrial cancer is progressing quickly, with no dose-limiting toxicities reported.

Development PipelineNextCure recently expanded its antibody-drug conjugate pipeline with the acquisition of global rights for SIM0505, diversifying its approach by leveraging two distinct payloads.

PartnershipsNextCure's focus on ADCs and its partnership with Simcere, who has several ADC programs in development, provides potential for addressing resistant tumors.

Bears Say

Competitive LandscapeThe B7-H4 ADC landscape remains competitive with several clinical stage players, posing a challenge for NextCure.

Market CompetitionCDH6 ADC development landscape is becoming increasingly competitive, with significant clinical-stage competitors setting the bar for efficacy.

NextCure News

NextCure’s Chief Scientific Officer Resigns

NextCure ( ($NXTC) ) has issued an update. On August 21, 2025, Solomon Langermann, Ph.D., resigned from his...

12d ago

NXTC

NextCure Reports Q2 2025 Results and Strategic Updates

Nextcure ( ($NXTC) ) has released its Q2 earnings. Here is a breakdown of the information Nextcure presented...

30d ago

NXTC

Closing Bell Movers: Intel slides after quarterly report

In the early hours of the evening session, U.S. equity futures were largely mixed, with every index continuing...

1M ago

ADT

NextCure presents new preclinical data on osteogenesis imperfecta treatment

NextCure (NXTC) announced the presentation of new preclinical data in a well-established model of osteogenesis imperfecta demonstrating that...

1M ago

NXTC

NextCure files to sell 339,000 shares of common stock for holders

The company will not receive any of the proceeds from the sale of its common stock by the...

2M ago

NXTC

NextCure price target lowered to $15 from $36 at Piper Sandler

Piper Sandler analyst Edward Tenthoff lowered the firm’s price target on NextCure (NXTC) to $15 from $36 and...

2M ago

NXTC

NextCure Implements Reverse Stock Split on Nasdaq

NextCure ( ($NXTC) ) has provided an update. On July 14, 2025, NextCure, Inc. implemented a one-for-twelve reverse...

2M ago

NXTC

Upcoming Stock Splits This Week (July 14 to July 18) – Stay Invested

These are the upcoming stock splits for the week of July 14 to July 18, based on TipRanks’ Stock...

2M ago

GORV

HTOO

NextCure trading halted, news pending

19:50 EDT NextCure (NXTC) trading halted, news pending Published first on TheFly – the ultimate source for real-time,...

2M ago

NXTC

NextCure Announces One-for-Twelve Reverse Stock Split

NextCure ( ($NXTC) ) has issued an update. On July 10, 2025, NextCure, Inc. announced that its board...

2M ago

NXTC

NextCure Approves Key Decisions at Annual Meeting

NextCure ( ($NXTC) ) has provided an update. On June 20, 2025, NextCure held its 2025 Annual Meeting...

3M ago

NXTC

NextCure Enters Licensing Agreement with Simcere Zaiming

The latest announcement is out from NextCure ( ($NXTC) ). On June 13, 2025, NextCure, Inc. entered into...

3M ago

NXTC

NextCure, Simcere Zaiming announce strategic partnership

NextCure (NXTC) and Simcere Zaiming, an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group, announced a...

3M ago

NXTC

Buy Rating Affirmed for NextCure: Promising LNCB74 Trial Progress and Competitive Edge in B7-H4 ADC Landscape

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on NextCure (NXTC – Research Report), retaining the...

4M ago

NXTC

NXTC FAQ

What was NextCure Inc’s price range in the past 12 months?

NextCure Inc lowest stock price was $2.69 and its highest was $19.20 in the past 12 months.

What is NextCure Inc’s market cap?

NextCure Inc’s market cap is $13.22M.

When is NextCure Inc’s upcoming earnings report date?

NextCure Inc’s upcoming earnings report date is Oct 30, 2025 which is in 53 days.

How were NextCure Inc’s earnings last quarter?

NextCure Inc released its earnings results on Aug 07, 2025. The company reported -$11.29 earnings per share for the quarter, missing the consensus estimate of -$4.615 by -$6.675.

Is NextCure Inc overvalued?

According to Wall Street analysts NextCure Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does NextCure Inc pay dividends?

NextCure Inc does not currently pay dividends.

What is NextCure Inc’s EPS estimate?

NextCure Inc’s EPS estimate is -3.98.

How many shares outstanding does NextCure Inc have?

NextCure Inc has 2,676,110 shares outstanding.

What happened to NextCure Inc’s price movement after its last earnings report?

NextCure Inc reported an EPS of -$11.29 in its last earnings report, missing expectations of -$4.615. Following the earnings report the stock price went down -4.51%.

Which hedge fund is a major shareholder of NextCure Inc?

Currently, no hedge funds are holding shares in NXTC

NextCure Stock Smart Score

Neutral

Fundamentals

Return on Equity

-104.07%

Trailing 12-Months

Asset Growth

-53.51%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

NextCure Inc

NextCure, Inc. (NXTC) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. The company's approach is centered around its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (FIND-IO) platform, which enables the identification of targets for new immunotherapies. NextCure's core products focus on addressing unmet medical needs in oncology through innovative therapeutic solutions.

NextCure (NXTC) Earnings & Revenues

Historic Earnings Reports

NXTC Stock 12 Month Forecast

Average Price Target

$17.50

▲(260.82% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","28":"$28","9.25":"$9.25","15.5":"$15.5","21.75":"$21.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,9.25,15.5,21.75,28],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.89,6.052307692307692,7.214615384615384,8.376923076923077,9.53923076923077,10.701538461538462,11.863846153846154,13.026153846153846,14.188461538461539,15.350769230769231,16.513076923076923,17.675384615384615,18.837692307692308,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.89,5.859999999999999,6.83,7.8,8.77,9.739999999999998,10.71,11.68,12.649999999999999,13.620000000000001,14.59,15.559999999999999,16.53,{"y":17.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.89,5.667692307692308,6.445384615384615,7.223076923076922,8.00076923076923,8.778461538461539,9.556153846153846,10.333846153846153,11.111538461538462,11.889230769230767,12.666923076923077,13.444615384615386,14.222307692307691,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.48,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.72,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.44,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.48,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.32,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.96,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.92,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.25,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.24,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.76,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.23,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.89,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >